Kazakhstan vs Singapore: The number of people with susceptibility test result for rifampicin
Kazakhstan
99.88
in 2021
Singapore
98.69
in 2021
Kazakhstan rank
32nd
Singapore rank
35th
The number of people with susceptibility test result for rifampicin over time
- Kazakhstan
- Singapore
How they compare
Kazakhstan currently reports 99.88 against 98.69 in Singapore, a difference of 1.19.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Singapore ahead.
Kazakhstan ranks 32nd and Singapore ranks 35th of 146 countries.
Across the 2 decades both report, Kazakhstan averaged higher in 1 and Singapore in 1.
Head to head by decade
| Decade | Kazakhstan | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 82.55 | 97.43 | 14.88 | Singapore |
| 2020s | 99.9 | 98.42 | 1.48 | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Kazakhstan or Singapore?
- Kazakhstan, at 99.88 against 98.69 in Singapore as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Kazakhstan and Singapore?
- 1.19, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Singapore?
- 5 years are reported by both, from 2017 to 2021.
- How do Kazakhstan and Singapore rank globally for the number of people with susceptibility test result for rifampicin?
- Kazakhstan ranks 32nd and Singapore ranks 35th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.